EyePoint’s Duravyu falls short to Eylea in Phase III trial
EyePoint’s stock dropped 67% after its potential Eylea (aflibercept) competitor Duravyu fell short in a Phase III trial…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…
Age-related macular degeneration treated with stem cell implants improves vision
Stem Cells Age-related macular degeneration (AMD) causes about half of all causes of blindness in older people. The…
New mRNA vaccine shows promise for preventing blindness
Excessive blood vessel growth in the retina at the back of the eye is a primary driver of…
New intramuscular mRNA vaccine offers easier alternative to treat neovascular eye diseases
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina…
New research aims to use eyedrops to lower lifetime risk of nearsightedness complications
For the first time, researchers are leading a national study to see if the onset of nearsightedness can…
Guidelines for Charles Bonnet Syndrome could reduce ‘unnecessary anxiety’, advocates say
Bernadette Glass said her “biggest fear” was not being believed when she started having visual hallucinations three years…